Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Open Access
- 24 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 11 (2), 308-325
- https://doi.org/10.1158/2159-8290.cd-20-1408
Abstract
In a phase II clinical trial, personalized antibodies plus molecularly targeted chemotherapy improved median overall survival and the one-year survival rate in patients with gastroesophageal adenocarcinoma relative to historical survival data.Other Versions
Funding Information
- NIH (CA178203-01A1)
- University of Chicago Comprehensive Cancer Center (P30CA014599)
This publication has 101 references indexed in Scilit:
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialThe Lancet Oncology, 2013
- Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor TissueClinical Proteomics, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric CancerCancer Research and Treatment, 2011
- Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trialAnnals of Oncology, 2011
- Gastrointestinal cancer and brain metastasisCancer, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary TumorsClinical Cancer Research, 2009
- Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II TrialsCancer Research and Treatment, 2009